Search
Enlarge Text | Printable Version | Sitemap | Contact us
People
Upcoming Events
Title: Dr. Job Title: Research Fellow and Lecturer Tel: +44 (0)131 650 2453 Fax: +44 (0)131 651 4278 Email: james.mittra@ed.ac.uk Building: ESRC Innogen Centre, The University of Edinburgh, Old Surgeon's Hall, High School Yards, Edinburgh, EH1 1LZ Room Number: G.33
James Mittra is an Innogen Research Fellow and lecturer at the University of Edinburgh. James is interested in innovation and regulation of life science industries and translational medicine. His academic background is in sociology and philosophy, although his PhD research on the impact of new types of genetic information on the UK life assurance industry, which was conducted in the sociology department at Warwick University, drew on broader interests in philosophy, political theory, social policy and history. James is currently supervising 3 PhD students, 2 MSc students and 1 BSc honour's student.
Journal Publications
Mittra, James, Tait, Joyce and Wield, David (2011) 'From maturity to value-added innovation: lessons from the pharmaceutical and agro-biotechnology industries', Trends in Biotechnology, Vol 29, No 3, pp. 105-109
Mittra, James (2008) 'Impact of the Life Sciences on Organisation and Management of R&D in Large Pharmaceutical Firms', International Journal of Biotechnology, Vol 10, No 5, pp. 416-440Mittra, James (2007) 'Predictive Genetic Information and Access to Life Assurance: The Poverty of Genetic Exceptionalism', Biosocieties, Vol.2, Issue 3, pp.349-373
Mittra, James. (2007) 'Marginalising "Eugenic Anxiety" through a Rhetoric of "Liberal Choice": A Critique of the House of Commons Select Committee Report on Reproductive Technologies', New Genetics and Society, Vol.26, Issue 2, pp. 159-179
Mittra, James (2007) 'Life Science Innovation and the Re-structuring of the Pharmaceutical Sector: Mergers, Acquisitions and Strategic Alliances', Technology Analysis and Strategic Management, Vol.19, Issue 3, pp. 279-301
Mittra, James (2006) 'The Socio-Political Economy of Pharmaceutical Mergers: A Case study of Sanofi and Aventis', Technology Analysis and Strategic Management, Vol.18, Issue 5, pp. 473-496
Mittra, James (2006) '"Genetic Exceptionalism" and Precautionary Politics: Regulating for Uncertainty in Britain's Genetics and Insurance Policy Process', Science and Public Policy, Vol.33, Issue 8, pp. 585-600
Working Paper
Yoruk, D. and Mittra, J. (2009) 'Mid Pharma: How Big is it and Where is it Going?', Innogen Working paper 81
Other Publications
Mittra, James, Tait, Joyce and Wield, David (2011) 'The Future of Pharmaceutical Innovation: New Challenges and Opportunities', Innovations in Pharmaceutical Technology, Mar 2011, pp. 32-34
Mittra, James and Williams, Robin (2007) 'Evolution of the Life Science Industries', Technology Analysis and Strategic Management, Special Issue, Vol.19, Issue 3, pp.251-255
Tait, Joyce and Mittra, James (2006) 'Singing from the same Hymn Sheet:: Can Genomics Harmonise with Chemistry?' CHEManager, August, 2006, p. 14
Mittra, James (2005) 'Pharmaceutical Industries: Do They Prefer Treatment to Cure?' The Biochemist Vol.27, Issue 3, pp.32-34
Mittra, James (2004) 'Genetics and Life Assurance: Should we Legislate?' ESRC Genomics Network Newsletter, Issue 1, September 2004 (opinion piece in which my arguments against legislation were followed by a response by Sir John Sulston)
Tait, Joyce and Mittra, James (2004) 'Industry Challenges', Chemistry and Industry, 6 December, 2004, No. 23, p. 24
Tait, Joyce and Mittra, James (2005) 'Big Pharma: Coping with Complexity', ESRC Genomics Network Newsletter, Issue 2, June 2005
Reports/Policy Briefs
Mittra, James and Tait, Joyce (2009) 'Stem Cells' Riskbrigde Report, Chapter 8, p224 - p268, published by EU,
Mittra, James (2009) Riskbridge Conference Proceedings, Brussels, 26-27 March 2009
Mittra, James, Suk, Jonathan and Tait, Joyce (2007) 'Risk Governance of Stem Cells as Therapeutic Products', RiskBridge essay, May 2007
Mittra, James (2007) 'Changing Strategies of Big Pharma', Innogen Policy Brief
Mittra, James (2007) 'GlaxoSmithKline and the Reorganization of R&D', Innogen Case Study Prepared for Executive Development Programme, 25-27 April 2007
Mittra, James (2007) 'Herceptin and the Politics of Drug Regulation', Innogen Case Study Prepared for Executive Development Programme, 25-27 April 2007
Mittra, James and Tait, Joyce (2006) 'Public-Private Partnerships in Translational Medicine: Scotland Translational Medicine Research Collaboration', Case study prepared for OECD Expert workshop on Emerging Research Models for the Delivery of Health Innovation (this case study will soon be published in an OECD report)
Conference/Seminar Talks
Mittra, James (2008) 'Genetic Information and Access to Life Assurance: The Poverty of Genetic Exceptionalism', EGN Network Conference, October 28th, 2008
Mittra, James (2008) ‘Management Responses to Stem Cell Risks’, EC Riskbridge Workshop, Gorizia, Italy, May 13th, 2008
Mittra, James (2008) ‘Issue Framing in the Stem Cell Risk Field’, EC Riskbridge Workshop, Gorizia, Italy, May 12th, 2008
Mittra, James (2008) ‘Interviewing Elite Groups in Biomedicine: Experiences from the Field’, PFGS Regional Meeting, Genomics Forum, University of Edinburgh, 14 April, 2008
Mittra, James (2008) ‘Risk Governance of Stem Cells as Therapeutic Products and Broader Implications for Innovation’, PEALS Spring Symposium (The Identification, Regulation and Implications of Risk Within Stem Cell Research), 10-11 April, 2008, Durham Castle (Invited)
Mittra, James(2007) ‘Public-Private Partnerships to Exploit Translational Medicine: The Translational Medicine Research Collaboration (TMRC) and its Implications for the Future of Pharmaceutical Innovation’, ESRC Genomics Network Conference, London, 25th October, 2007
Mittra, James (2007) ‘’Risk Governance and Regulation of Stem Cells as Therapeutic Products’, Stem Cells: European Business Summit, Edinburgh, 12th October 2007 (paper also delivered at ESRC Genomics Network Conference, London, 25th October, 2007
Mittra, James (2007) ‘Insurance and Healthcare in the Molecular Age’, invited discussant for Biodata, Health and Security Research Workshop, Institute for Advanced Studies, University of Lancaster, June 29th 2007 (Invited)
Mittra, James and Tait, Joyce (2006) ‘Public-Private Partnerships in Translational Medicine: Scotland’s Translational Medicine Research Collaboration (TMRC)’, Paper presented at OECD Expert Workshop, ‘Emerging Research models for the Delivery of Health Innovation’, Paris, November 20-21 2006
Tait, Joyce and Mittra, James(2006) ‘Singing from the Same Hymn Sheet: Can Genomics Harmonise with Chemistry?’, SCIpharm, Wednesday 17 May 2006, Edinburgh International Conference Centre
Mittra, James (2005) 'Regulation of Human Reproductive Technologies in the UK: Libertarian Values Versus Communitarian Fears' – Norwegian Academy of Science and Letters, 16th September 2005 – Workshop organised by the Seminar in Science Studies, University of Oslo (invited)
Mittra, James (2004) ‘The Merger of Sanofi and Aventis: The Encroachment of Politics on ‘Business Rationality’ – Innogen Retreat, University of Cranfield, 22 October, 2004
Mittra, James(2004) ‘Life Science Innovation and the Pharmaceutical Sector’, Innogen/Cesagen Joint Workshop, University of Edinburgh, 1 April, 2004
Mittra, James (2003) ‘Innovation Processes in Genomics-Related Industry Sectors’, Innogen Annual Retreat, The Burn, March 2003
Mittra, James (2001) ‘Genetic Testing and Life Insurance: A Legislative Nightmare’, Postgraduate Forum on Genetics and Society 5th Colloquium, University of Nottingham, June 20 2001
Mittra, James ‘The Use and Abuse of Biology: Eugenics, Evolutionary Psychology and the Future of Social Science’, Social Theory Seminar Series, Department of Sociology, University of Warwick, November 19 2001
James uses interdisciplinary methods and analytical frameworks to improve understanding of the complex and dynamic ways in which the life sciences are affecting the nature and process of technological innovation within the pharmaceutical and healthcare sectors; the emergence and development of translational research; and risk-governance issues associated with the development of stem cells as therapeutic products.
His interests include:
James is currently involved in the following Innogen projects:
Completed Innogen projects include:
Research Supervision
James is currently supervising 6 students.
Sam Foster: Decision making and the Human Fertilisation and Embryology Authority; Interactions in the regulatory arena of embryonic stem cell research
Emma King: Innovation and regulation interactions in the development of clinical stem cell therapiesHeather Lowrie: Emerging risks in the insurance industry
Caroline Woodside, MSc Translational Medicine: Catalysing academic research translation - key drivers and strategies to direct good practice, funding, and outcome deliveryProject Description: Through two case studies and a series of stakeholder interviews this project will attempt to better understand the barriers and drivers of the translation of scientific understanding and knowledge of disease into clinical benefit. It will also develop an optimal framework that will effectively direct academic translation of research for clinical purposes.
Prof Heinz Zimmerman, MSc Translational Medicine: Attitude, knowledge and implementation of Translational Research/Medicine (TR/TM) at the medical faculty of the University of Bern Project Description: The aims of this project are to 1) define the distribution of basic research, bench to bedside research, TR/TM (bench to bedside and back) and other relevant types of research amongst the medical faculty at the University of Bern; and 2) explore the attitude, knowledge and understanding of TM/TR amongst the medical faculty at the University of Bern. This project will generate data on the proportion of TR/TM compared to other kinds of research and improve knowledge and understanding of the barriers to conducting TR/TM.
Sophie Shott, Biology Honour’s: A Review of the National Institutes of Health (NIH) Translational Research Strategy and its Implementation Project Description: This project will provide a comprehensive review of the National Institutes for Health strategy to facilitate Translational Medicine, and critically explore some of the key methods of implementation.
back
|
Printable Version |
Sitemap |
Contact us
.JPG)
